Abstract | AIMS/HYPOTHESIS: METHODS: In a randomised placebo-controlled crossover design using nine patients with non-diabetic, HIV-associated lipodystrophy, we assessed whether (1) overnight administration of a low dose of acipimox and/or (2) insulin-induced suppression of NEFA flux altered circulating plasma levels of adiponectin, IL-18, TNF-α and IL-6 in the basal condition and in a two-stage euglycaemic-hyperinsulinaemic clamp combined with stable isotopes ( insulin infusion rates 20 mU m(-2) min(-1) and 50 mU m(-2) min(-1)). RESULTS:
Insulin decreased plasma NEFA in a dose-dependent manner (p < 0.0001). Acipimox reduced basal plasma NEFAs and plasma NEFAs during the low-dose insulin infusion compared with placebo (p < 0.0001 for acipimox effect). Plasma adiponectin and plasma IL-18 were reduced during both situations where lipolysis was inhibited (p < 0.0001 for acipimox effect; p < 0.0001 and p < 0.05 for insulin effect on plasma adiponectin and plasma IL-18, respectively). In contrast, plasma IL-6 and plasma TNF-α did not change during low NEFA concentrations. CONCLUSIONS/INTERPRETATION:
|
Authors | B Lindegaard, S Ditlevsen, P Plomgaard, B Mittendorfer, B K Pedersen |
Journal | Diabetologia
(Diabetologia)
Vol. 56
Issue 9
Pg. 2034-43
(Sep 2013)
ISSN: 1432-0428 [Electronic] Germany |
PMID | 23811808
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adiponectin
- Insulin
- Interleukin-18
- Pyrazines
- acipimox
|
Topics |
- Adiponectin
(blood)
- Cross-Over Studies
- Female
- Humans
- Insulin
(therapeutic use)
- Interleukin-18
(blood)
- Lipodystrophy
(blood, drug therapy)
- Lipolysis
(drug effects)
- Male
- Middle Aged
- Pyrazines
(therapeutic use)
|